-
I just had a patient present for consultation, concerned hed transmitted herpes simplex virus (HSV) to two new sexual partners, despite a lack of symptoms or obvious lesions, and expressing concern about the adequacy of suppressive acyclovir therapy. He had tried to convince both new partners it was not him! I had to disappoint him.
-
A second factor XA inhibitor (novel oral anticoagulant, NOAC), after rivaroxaban, has been approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Apixaban is marketed by Bristol-Myers Squibb and Pfizer as Eliquis.
-
Do the presence or absence of acetylcholine receptor (AchR)-binding antibodies (Abs) and muscle-specific kinase (MuSK) Abs correlate with disease phenotype in myasthenia gravis (MG)?
-
Chesnut et al have performed the first randomized, controlled trial to evaluate the benefit of intracranial pressure (ICP) monitoring on outcome after severe traumatic brain injury (TBI).
-
-
Although many children with a first febrile seizure will have had a simple febrile seizure, a relatively common and benign childhood illness, a subset will present in febrile status epilepticus, the most severe in the spectrum of febrile seizures.
-
In this issue: Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions.
-
Based on the prior work of patrick kwan and martin brodie, The efectiveness of the first antiepileptic drug (AED) in new-onset epilepsy is nearly 50%.
-
Dr. Henchcliffe reports she is on the speakers bureau and advisory board for Allergan and Teva; speakers bureau for Boehringer-Ingelheim, GlaxoSmith-Kline, and Novartis; advisory board for Merz; and is a consultant for Gerson Lehman Group and Guidepoint Global.
-
